adenosine receptor knockout mice are protected against ischemia-and myoglobinuria-induced renal failure.
acute renal failure; histamine; ischemic-reperfusion injury ACUTE RENAL FAILURE (ARF) is a major contributor of perioperative mortality and morbidity (7, 20) . Ischemic-reperfusion (I/R) injury, toxic nephropathy, and myoglobinuria all can lead to ARF, which is frequently complicated by many other life-threatening complications including sepsis and multiorgan failure (1, 20, 21) . The prognosis for patients with ARF is poor (with mortality ϳ50%) and has changed little over the past 40 years (1, 7) .
We demonstrated previously that adenosine receptor (AR) modulations significantly affect renal function after I/R injury in rats (14, 16, 17) . All four known AR subtypes (A 1 , A 2a , A 2b , and A 3 ) are expressed in the kidney (18, 28) , but the function of A 3 AR is unknown. We recently showed that preischemic activation of A 3 ARs exacerbates renal failure after I/R injury (14) . Conversely, preischemic administration of an A 3 AR antagonist protected the rat kidney against I/R injury.
In this study, we aimed to extend our previous findings of modulation of A 3 ARs on renal function after I/R injury utilizing mice deletionally lacking A 3 ARs [A 3 AR knockout (A 3 KO)] (23, 26) . We hypothesized that A 3 KO mice would be endogenously protected against I/R injury. We also hypothesized that preischemic activation or inhibition of A 3 ARs would worsen and protect, respectively, renal failure after I/R-or myoglobinuria-induced renal failure in mice. A 3 AR activation degranulates mast cells and increases plasma histamine in rodents (4, 6, 22, 26) . Therefore, we investigated the mechanism of A 3 AR modulation of renal failure by using selective blockers of histamine receptors and an effector (compound 48/80) that increases endogenous histamine release.
METHODS

A3KO mice. Homozygous A3KO (A3
Ϫ/Ϫ ) mice breeding pairs were provided by Merck Research Laboratories (West Point, PA). Generation and initial characterization of the A 3KO mice have been described in detail previously (23, 26) . The A 3KO mice were obtained after they were backcrossed against C57BL/6 mice for 12 generations to obtain a congenic line. C57BL/6 mice (Harlan Laboratories, Indianapolis, IN) served as background A 3 ϩ/ϩ controls (C57). Renal injury protocol. A 3KO and C57 mice (25-30 g body wt) were anesthetized with pentobarbital sodium (50 mg/kg or to effect ip) and placed supine on a heating pad under a warming light to maintain body temperature between 36 and 38°C. Additional pentobarbital sodium was given as needed on the basis of response to tail pinch. Bilateral flank incisions were made, and the left kidney was subjected to 30 min of ischemia with microaneurysm clips after right nephrectomy. The duration of ischemia was chosen to maximize reproducibility of renal injury and to minimize mortality in these mice. Separate groups of C57 and A3KO mice were injected with 8.5 mg/kg glycerol intramuscularly after 16 h of water deprivation to induce myoglobinuric renal injury. Some C57 mice were pretreated either with 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(Ϯ)-dihydropyridine-3,5 dicarboxylate (MRS-1191; 1 mg/kg ip), a selective A 3 AR antagonist, or with 0.125 mg/kg N 6 -(3-iodobenzyl)-N-methyl-5Ј-carbamoyladenosine (IB-MECA; 0.0625, 0.125, 0.25, 0.5, 1, and 2 mg/kg ip), a selective A 3 AR agonist, 15 min before renal ischemia or glycerol injection.
To determine whether histamine release by mast cell degranulation induced by IB-MECA plays any role in lethality and exacerbation of renal injury by A 3 AR activation, some C57 mice were pretreated with 10 mg/kg diphenylhydramine or 10 mg/kg ranitidine ip 30 min before 1 mg/kg IB-MECA. Some A 3KO and C57 mice were pretreated with 5 mg/kg of compound 48/80 (to degranulate mast cells) 15 min before being subjected to renal I/R injury.
Assessment of renal injury. Renal function was assessed by measuring plasma creatinine 24 h after renal ischemia or glycerol injection by using a commercially available colorimetric method (Sigma). For histological preparations, explanted kidneys were bisected along the long axis and were fixed in 10% formalin solution overnight. After automated dehydration through a graded alcohol series, transverse kidney slices were embedded in paraffin, sectioned at 5 m, and stained with hematoxylin-eosin. Morphological assessment was performed by an experienced renal pathologist (V. D. D'Agati) who was blinded to the treatment for each animal. A grading scale of 0-4, as outlined by Jablonski et al. (10) , was used for the histopathological assessment of I/R-or myoblobinuria-induced damage of the proximal tubules.
Measurement of plasma histamine levels. Plasma histamine levels were measured in A 3KO and C57 mice 20 min after IB-MECA or compound 48/80 treatment (5 min after initiation of renal ischemia) by using an ELISA specific for mice (RDI, Flanders, NJ) according to the manufacturer's instructions.
PCR for A 3 ARs. We analyzed the presence of the wildtype or mutant A3 AR DNA in C57 and A3KO mice by PCR. To differentially confirm the genotype of A3KO and C57 mice, primers were designed to recognize the 5Ј-and 3Ј-end of the full-length wild-type A 3 AR (sense: 5Ј-GA-CTGGCTGAACATCACCTACAT-3Ј and antisense: 5Ј-AT-AGAAGTGCATCTTGACTTGCAG-3Ј) and the PGKneo insert (sense: 5Ј-CTATGACTGGGCACAACAGACAAT-3Ј and antisense: 5Ј-ATCAGCCATGATGGATACTTTCTC-3Ј) in A 3KOs (23) . All primers were purchased from Sigma GenoSys (The Woodlands, TX). Genomic DNA was isolated from mouse tails by using the Wizard Genomic DNA extraction kit (Promega, Madison, WI). DNA concentrations were determined by using spectrophotometric absorbance at 260/280. PCR was performed with Taq polymerase (Promega). Genomic DNA (0.2 g) was used as a template and amplified for 30 cycles with a PTC-200 thermal cycler (MJ Research, Waltham, MA) using a primer annealing temperature of 60°C. The products were resolved in a 6% polyacrylmide gel and stained with Syber green (Roche, Indianapolis, IN) for analysis with a FluorS Multi Imager (Bio-Rad, Hercules, CA).
Chemicals. Unless otherwise specified, all reagents were purchased from Sigma (St. Louis, MO).
Statistics and data analysis. The data were analyzed with Student's t-test when comparing means between two groups or with one-way analysis of variance plus Dunnett post hoc multiple comparison test to compare mean values across multiple treatment groups.
RESULTS
Genotyping of wild-type and A 3 KO C57 mice.
To confirm the genotypes of mice used in these studies, genomic DNA extracted from the tail was analyzed by PCR for the expression of the full-length A 3 AR (wildtype or C57 mice) or the plasmid insert (PGKneo) originally used to disrupt the A 3 AR gene (A 3 KO mice) (23) . The full-length A 3 AR (ϳ220 bp) was only detected in C57 wild-type mice, whereas the PGKneo insert (ϳ290 bp) was only detected in the A 3 KO mice ( Fig. 1) .
Renal function assessment. C57 control and A 3 KO mice that underwent sham operations had similar baseline hemodynamic values (heart rate and blood pressure) and renal function [creatinine (Cr) ϭ 0.3 Ϯ 0.1 mg/dl, n ϭ 3, for C57, and 0.3 Ϯ 0.1 mg/dl, n ϭ 3, for A 3 KO]. However, 24 h after renal I/R injury, A 3 KO Fig. 1 . Representative PCR products using specific primers of mouse A3 adenosine receptor (AR; C57 mice) and PKGneo [A3 AR knockout (A3KO) mice]. Total DNA (0.2 g, extracted from tail) was used in each PCR reaction. DNA encoding A3 AR was only detected in C57 control mice (n ϭ 2), whereas the PKGneo insert was only detected in A3KO mice (n ϭ 4). mice had significantly lower plasma creatinines (Cr ϭ 0.7 Ϯ 0.1 mg/dl, n ϭ 8) compared with C57 controls (Cr ϭ 3.0 Ϯ 0.3 mg/dl, nϭ 8, P Ͻ 0.05, Fig. 2) . A 3 KO mice were also protected against myoglobinuric renal injury compared with control mice as demonstrated by reduced creatinines at 24 h (Cr ϭ 1.8 Ϯ 0.3 mg/dl, n ϭ 8 for A 3 KO, vs. 4.1 Ϯ 0.2 mg/dl, n ϭ 4, for C57, P Ͻ 0.05, Fig. 2) .
To further illustrate the role of the A 3 AR in modulating renal function after injury, control C57 mice were pretreated with an A 3 AR antagonist or agonist before I/R or glycerol-induced myoglobinuric injury. C57 mice pretreated with MRS-1191 (a selective A 3 AR antagonist) demonstrated improved renal function after either I/R-induced or glycerol-induced renal injury (Cr ϭ 1.8 Ϯ 0.2 mg/dl, n ϭ 9, for MRS-1191ϩI/R, or 3.1 Ϯ 0.2 mg/dl, n ϭ 6, for MRS-1191ϩglycerol, respectively, P Ͻ 0.05; Fig. 2 ) compared with I/R or glycerol injury alone. In contrast, C57 mice pretreated with IB-MECA, a selective A 3 AR agonist, failed to survive the ischemic period at doses of 2 (n ϭ 6), 1 (n ϭ 6), 0.5 (n ϭ 6), or 0.25 mg/kg (n ϭ 6). At 0.125 mg/kg IB-MECA, C57 mice survived renal I/R injury and demonstrated significantly worsened renal function (Cr ϭ 4.5 Ϯ 0.2 mg/dl, n ϭ 6, P Ͻ 0.05, compared with I/R injury alone; Fig. 2 ). C57 mice pretreated with 0.0625 mg/kg IB-MECA before renal I/R did not exhibit significantly worsened renal function (Cr ϭ 3.4 Ϯ 0.2 mg/dl, n ϭ 4). Selective A 3 AR agonist (Cr ϭ 0.6 Ϯ 0.1 mg/dl, n ϭ 5, after 0.125 mg/kg IB-MECA) or antagonist (Cr ϭ 0.6 Ϯ 0.1 mg/dl, n ϭ 4, after 1 mg/kg MRS-1191) has no impact on renal protection observed in A 3 KO mice subjected to I/R injury.
IB-MECA (0.5 mg/kg) also exacerbated renal function in C57 mice after myoglobinuric renal injury (Cr ϭ 4.8 Ϯ 0.1 mg/dl, n ϭ 4, P Ͻ 0.05, compared with myoglobinuric injury alone). C57 mice injected with IB-MECA (2 mg/kg) alone without I/R or myoglobinuric injury survived and showed normal renal function. When C57 (n ϭ 4) and A 3 KO (n ϭ 4) mice were pretreated with compound 48/80 (5 mg/kg) and subjected to renal I/R injury, all the mice died during renal ischemia.
Increase in plasma histamine by IB-MECA or compound 48/80 is lethal when associated with renal ischemia. A 3 AR activation causes mast cell degranulation and histamine release in rodents (6, 22, 26) . We questioned whether the systemic elevations in histamine played a role in the lethality and impaired renal function of A 3 AR activation coupled with renal ischemia and reperfusion. We measured plasma histamine levels in A 3 KO and C57 mice after IB-MECA or compound 48/80 (induces mast cell degranulation) pretreatment by using a mouse-specific ELISA. A 3 KO and control C57 mice that underwent sham operations had similar baseline plasma histamine levels (4.6 Ϯ 1.0 and 5.0 Ϯ 1.6 ng/ml, respectively, n ϭ 3). IB-MECA (1 mg/kg) increased plasma histamine concentration to 226 Ϯ 24.8 ng/ml in C57 mice (n ϭ 6) and to 31.0 Ϯ 4.3 ng/ml in A 3 KO mice (n ϭ 4, P Ͻ 0.01 vs. C57) 20 min after injection (5 min after initiation of renal ischemia). Plasma histamine concentrations increased in C57 and A 3 KO mice pretreated with compound 48/80 (320 Ϯ 8.8 ng/ml, n ϭ 4, and 249 Ϯ 29.3 ng/ml, n ϭ 5, respectively).
Because all control C57 mice pretreated with compound 48/80 or 0.25-2.0 mg/kg IB-MECA and all A 3 KO mice pretreated with compound 48/80 died during ischemia, we questioned whether inhibition of histamine receptor subtypes would alter lethality or renal function. Thirty minutes of pretreatment with H 1 (diphenylhydramine, 10 mg/kg ip) but not with H 2 (ranitidine, 10 mg/kg ip) histamine receptor antagonist prevented death in C57 mice treated with IB-MECA Fig. 2 . Comparison of mean creatinine measured from sham-operated C57 mice (C57 sham; n ϭ 3), sham-operated A3KO mice (A3KO sham; n ϭ 3), C57 mice subjected to ischemia and reperfusion (C57 IR; n ϭ 8), A3KO mice subjected to ischemia and reperfusion (A3KO IR; n ϭ 8), C57 mice pretreated with IB-MECA before ischemia and reperfusion (IB-MECA IR; n ϭ 6), C57 mice pretreated with MRS-1191 before ischemia and reperfusion (MRS IR; n ϭ 9), C57 mice subjected to glycerol injury (C57 Glyc; n ϭ 4), A3KO mice subjected to glycerol injury (A3KO Glyc; n ϭ 8), C57 mice pretreated with IB-MECA before glycerol injury (IB-MECA Glyc; n ϭ 4), and C57 mice pretreated with MRS-1191 before glycerol injury (MRS Glyc; n ϭ 6). *P Ͻ 0.05 vs. sham-operated C57 mice. #P Ͻ 0.05 vs. C57 mice subjected to ischemia and reperfusion. %P Ͻ 0.05 vs. C57 mice subjected to glycerol injury. Error bars, 1 SE. and in C57 or A 3 KO mice treated with compound 48/80. However, pretreatment with diphenylhydramine did not protect renal function after I/R injury in C57 mice treated with IB-MECA (Cr ϭ 4.0 Ϯ 0.2 mg/dl, n ϭ 4). Similarly, when C57 mice were pretreated with diphenyhydramine before compound 48/80 and subjected to renal I/R, they survived renal ischemia but failed to show improved renal function compared with the I/R injury alone group (Cr ϭ 2.9 Ϯ 0.2 mg/dl, n ϭ 3). Therefore, although elevated plasma histamine and activation of the H 1 histamine receptor coupled with renal ischemia are lethal in mice, H 1 receptor activation alone cannot account for A 3 AR activation-mediated exacerbation of renal function.
Injured A 3 KO mice maintained improved renal histology. In Fig. 3 , enhanced renal protection of A 3 KO mice against I/R-and glycerol-mediated injury are further supported by representative histological slides. C57 control mice subjected to 30 min of renal ischemia (Fig. 3B ) or glycerol injection (Fig. 3C) followed by 24 h of reperfusion resulted in significant renal injury, as evidenced by severe tubular necrosis, medullary congestion and hemorrhage, and the development of proteinaceous casts. A 3 KO mice (Fig. 3, D and E) or C57 mice (Fig. 3, F and G) pretreated with the A 3 AR antagonist MRS-1191 before I/R-or glycerol-induced injury showed improved renal morphology. The Jablonski (10) scale histology grading scores are shown in Fig. 4 . Twenty-four hours after 30 min of renal ischemia or glycerol treatment in C57 control mice resulted in severe acute tubular necrosis (grade: 3.0 Ϯ 0.3, n ϭ 6, and 3.7 Ϯ 0.4, n ϭ 4, respectively). A 3 KO mice subjected to I/R or glycerol injury showed significant improvements in histological scoring compared with C57 mice subjected to I/R (grade: 0.7 Ϯ 0.5, n ϭ 4, and 1.7 Ϯ 0.3, n ϭ 4, respectively). Additionally, C57 mice pretreated with MRS-1191 before I/R or glycerol injury showed significant improvements in histological scoring compared with C57 mice subjected to I/R injury (grade: 2.1 Ϯ 0.2, n ϭ 5, and 2.3 Ϯ 0.3, n ϭ 4, respectively). IB-MECA-pretreated C57 mice subjected to I/R or glycerol injury failed to show statistically significant worsening histological injury compared with C57 mice (grade: 3.7 Ϯ 0.4, n ϭ 4, and 3.8 Ϯ 0.4, n ϭ 3, respectively).
DISCUSSION
The major findings of our study are the following: 1) mice deletionally lacking A 3 ARs are protected against both ischemic and myoglobinuric forms of renal injury, 2) blocking A 3 ARs protected and activating A 3 ARs worsened renal failure after I/R-and myoglobinuriainduced injury in C57 control mice, 3) high doses of the A 3 AR agonist (IB-MECA) coupled with renal ischemia are lethal in C57 mice presumably by degranulating resident mast cells and releasing histamine, and 4) blocking H 1 histamine receptors prevented A 3 AR agonist-or mast cell degranulation-induced mortality during renal ischemia in C57 control or A 3 KO mice.
In previous studies by our laboratory, we showed that preischemic A 1 or postischemic A 2a AR activation protects against renal I/R injury in rats (14, 16, 17) . In addition, we demonstrated in rats that A 3 AR activation with IB-MECA and inhibition with MRS-1191 worsened and protected, respectively, against I/R-induced renal failure (14) . In the present study, we utilized mice that lack A 3 ARs to further probe the role of A 3 ARs in renal I/R and myoglobinuric injury.
The A 3 AR subtype is the most recently characterized member of the AR family (5, 11) . Although the expression of the A 3 AR subtype in the kidney has been demonstrated (18, 28) , its function in the kidney is unknown. The present studies in mice agree with our previous studies in rats in that pretreatment with the highly selective A 3 AR agonist IB-MECA worsened renal I/R injury, whereas pretreatment with the highly selective A 3 adenosine antagonist MRS-1191 protected renal function after I/R injury (14) . Although MRS-1191 is a potent and selective antagonist of human A 3 receptors, it has only limited potency and selectivity at the mouse A 3 AR receptor (K i ϳ 1.42 M) (12, 13) . For this reason, we cannot rule out the possibility that MRS-1191 might act in part by blocking other AR subtypes. For this reason, the data derived from the use of A 3 KO mice are important to bolster the conclusion on the basis of the use of MRS-1191.
IB-MECA also exacerbated glycerol-induced myoglobinuric renal failure. Furthermore, mice lacking the A 3 AR exhibited endogenous protection against both I/Rinduced and myoglobinuric-induced renal injury. Because the A 3 AR agonist alone had no effect on renal function in both rats (14) and mice, it can be concluded that A 3 AR activation must be coupled with an I/R or myoglobinuric renal insult for the receptor to have a detrimental effect on renal function. The detrimental effects of preischemic A 3 AR agonist treatment on the kidney differs from the heart, where significant cardiac protection with A 3 AR agonist pretreatment has been reported (19) .
The mechanism(s) by which A 3 AR activation or inhibition exacerbates or protects against, respectively, renal injury remains to be determined. A 3 adenosine agonists cause apoptosis in multiple cell lines, including cardiomyocytes, human leukemia cell lines, and human proximal tubule (HK-2) cells, via incompletely characterized mechanisms (11, 15, 24) . Chronic A 3 AR activation or overexpression is detrimental to cell survival (11) . Moreover, overexpression of A 3 AR is Fig. 3 . Representative light microscopic photographs of outer medulla of the kidney. A: sham-operated C57 mice. B: C57 mice subjected to ischemia and reperfusion. C: C57 mice subjected to glycerol injury. D: A3KO mice subjected to ischemia and reperfusion. E: A3KO mice subjected to glycerol injury. F: C57 mice pretreated with MRS-1191 before ischemia and reperfusion. G: C57 mice pretreated with MRS-1191 before glycerol injury. Magnification, ϫ200.
embryologically lethal in mice with prominent fragmentation of DNA (27) . Additionally, mice deletionally lacking A 3 ARs are protected against cardiac I/R injury by unclear mechanisms (3, 8, 9) .
The A 3 AR activation degranulates resident mast cells, which results in the release of stored inflammatory mediators, including histamine and proteolytic enzymes, as well as other proinflammatory mediators (e.g., IL-␤ and TNF-␣) (6, 22) . We examined the role of mast cell degranulation and histamine release after A 3 AR activation utilizing histamine receptor blockers and by measuring plasma histamine concentrations. We demonstrate that the A 3 AR agonist IB-MECA profoundly increases plasma histamine levels in C57 mice (ϳ45-fold increase). In contrast, compound 48/80 increased histamine levels in both C57 and A 3 KO mice. It is interesting to note that IB-MECA increased plasma histamine levels even in A 3 KO mice by approximately sevenfold, although this increase is significantly less than that observed in C57 mice. It may be that IB-MECA has some additional mechanism of action to increase plasma histamine levels independently of A 3 AR activation.
We show that 0.125 mg/kg IB-MECA, a selective A3 AR agonist, worsened renal function after I/R renal injury. Moreover 0.5 mg/kg IB-MECA exacerbated renal injury after glycerol-mediated myoglobinuric renal injury. Surprisingly, C57 mice were very sensitive to A 3 AR agonist (IB-MECA) injection when subjected to renal ischemia, because doses Ն0.25 mg/kg were lethal. Moreover, degranulation of mast cells with compound 48/80 coupled with renal ischemia was also lethal in both C57 and A 3 KO mice. IB-MECA and compound 48/80 injections without renal ischemia were well tolerated in both A 3 KO and C57 mice. The mechanism of mortality after higher doses of IB-MECA (0.25-2 mg/kg) coupled with renal ischemia is likely related to H 1 histamine receptor activation. Systemic effects of histamine release on the cardiac and vascular systems likely account for mortality after high doses of IB-MECA. Death associated with elevated systemic histamine complicates the interpretation of A 3 ARmediated exacerbation of renal function after renal ischemia and is the major limitation of the present, in vivo approach.
Pretreatment with an H 1 histamine receptor blocker (diphenylhydramine) prevented death during renal ischemia in C57 mice treated with 1 mg/kg IB-MECA, whereas pretreatment with an H 2 histamine receptor blocker (ranitidine) failed to rescue C57 mice from death. Although C57 mice survived renal ischemia after H 1 histamine receptor antagonist and IB-MECA, their renal function was not improved. This indicates that an increase in plasma histamine concurrent with renal ischemia is lethal in mice because of H 1 histamine receptor activation. However, H 1 histamine receptor activation cannot account for exacerbation of renal function after ischemia-or glycerol-induced renal injury, because pretreatment with H 1 histamine blocker failed to improve plasma creatinine or histology. It remains to be determined whether other histamine receptor subtype blockades (H 2 , H 3 , or H 4 ) with or without concomitant H 1 histamine receptor blockade are required to protect against renal I/R injury.
We recognize that the background strain of mice is an important determinant of renal injury (2) . In this study, we utilized commercially available C57BL/6 mice as controls because the homozygous A 3 KO mice were backcrossed against C57BL/6 mice for 12 generations to obtain a congenic line. Backcrossing to this Fig. 4 . Jablonski grading scale scores for histological appearance of acute tubular necrosis from sham-operated C57 mice (n ϭ 3), shamoperated A3KO mice (n ϭ 3), C57 mice subjected to ischemia and reperfusion (n ϭ 6), A3KO mice subjected to ischemia and reperfusion (n ϭ 4), C57 mice pretreated with IB-MECA before ischemia and reperfusion (n ϭ 4), C57 mice pretreated with MRS-1191 before ischemia and reperfusion (n ϭ 5), C57 mice subjected to glycerol injury (n ϭ 4), A3KO mice subjected to glycerol injury (n ϭ 4), C57 mice pretreated with IB-MECA before glycerol injury (n ϭ 3), and C57 mice pretreated with MRS-1191 before glycerol injury (n ϭ 4). *P Ͻ 0.05 vs. sham-operated C57 mice. #P Ͻ 0.05 vs. C57 mice subjected to ischemia and reperfusion. %P Ͻ 0.05 vs. C57 mice subjected to glycerol injury. Error bars, 1 SE. extent makes a congenic line that is 99.99% genetically C57BL/6.
In conclusion, we demonstrate that mice lacking A 3 AR expression are protected against both I/R-induced and myoglobinuria-induced renal failure. Moreover, A 3 AR agonist and antagonist worsened and protected, respectively, I/R-and myoglobinuric-mediated renal injury in C57 control mice. The mechanism(s) of A 3 AR-mediated exacerbation of renal function after I/R or myoglobinuric injury and the signaling pathway(s) responsible for potent renal protection in A 3 KO mice remain to be determined. These findings further support the potential role of a selective A 3 AR antagonist for protection against perioperative renal failure.
